Lupin Limited expects to train more than 1,000 under graduates into pharma professionals by the year 2020 under its Learn and Earn Initiative, a senior company official said as per the PTI report. Lupin has launched its 'Learn and Earn' initiative in which candidate who has passed Standard 12 in the science stream with a minimum of 50 per cent marks but are facing financial constraints are taken for three-year-long course during which they are paid stipend and provided all the facilities.
Since 2011 Lupin has helped to create a total of 560 graduates with 181 students passing out this year (2018)," C Srinivasalu, senior vice president (HR) Lupin told reporters in Goa Thursday. "We expect to graduate more than 1,000 students by 2020 adding to the manpower resource of the pharmaceutical sector," Srinivasalu said adding that "most of these would be absorbed by Lupin."
The company has initiated the 'Learn and Earn Initiative' at its facilities in Goa, Tarapur (Maharashtra), Indore (MP), Aurangabad (Maharashtra) and Sikkim, he said. During the course period, the candidate undergoes five days on-the-job training with one day of classroom session, Srinivasalu said. Further, the students have to compulsorily work with Lupin for two years, after completing their course before they have their options open to join any other pharmaceutical firm.
Mumbai-headquartered Lupin has estimated that by the year 2020 they would be spending almost Rs 20 crore on this programme. This program will bridge the manpower requirement of pharmaceutical sector in a big way," he said. Addressing media, Yashwant Mahadik, president, global human resource, Lupin. said program was conceptualised in the year 2010 due an acute shortage of skilled manpower. "Historically, Lupin was recruiting 1,000 plus fresh graduates every year with no relevant job skill, and sensed that there was a need of job-ready graduates with appropriate technical and life skills," he said. Mahadik claimed that the main aim of this program was to "create a ready pool of talent in India to be part of the booming pharmaceutical sector.
Lupin’s Tarapur API Manufacturing Facility Inspected by US FDA
Pharma major Lupin announced the completion of a cGMP inspection carried out by the US FDA at its Tarapur facility. The inspection closed with one observation, a procedural deficiency. The inspection at the site was conducted between 27th and 31st August 2018 by three FDA investigators.
The inspection focused on cGMP compliance and also on the safety of Lupin’s Valsartan, Losartan and Irbesartan APIs (commonly known as ‘Sartans’) in light of the safety alert issued by Regulatory Authorities on the NDMA (classified as a probable human carcinogen) impurity in Valsartan API supplied by some companies. During the inspection, the US FDA concluded that the manufacturing processes of Lupin ‘Sartans’ are safe with no chance of presence of the NDMA impurity in the APIs.
Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership position in the Anti-TB segment.
Lupin is the 8th largest generics pharmaceutical company both in terms of market capitalization (30th June 2018, Bloomberg) and revenues (31st March 2018, Bloomberg LTM) globally. The Company is the 4th largest pharmaceutical player in the US by prescriptions (IQVIA MAT June 2018); 3rd largest Indian pharmaceutical company by global revenues (31st March 2018, Bloomberg LTM); 6th largest generic pharmaceutical player in Japan and 5th largest company in the Indian Pharmaceutical Market